On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines.